-$0.88 Earnings Per Share Expected for Global Blood Therapeutics Inc (GBT) This Quarter

Equities analysts predict that Global Blood Therapeutics Inc (NASDAQ:GBT) will announce earnings of ($0.88) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Global Blood Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.72) and the lowest estimate coming in at ($1.01). Global Blood Therapeutics posted earnings per share of ($0.94) in the same quarter last year, which indicates a positive year over year growth rate of 6.4%. The company is scheduled to announce its next quarterly earnings results on Tuesday, February 26th.

On average, analysts expect that Global Blood Therapeutics will report full-year earnings of ($3.36) per share for the current fiscal year, with EPS estimates ranging from ($3.49) to ($3.20). For the next fiscal year, analysts forecast that the company will post earnings of ($3.76) per share, with EPS estimates ranging from ($4.24) to ($3.03). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Global Blood Therapeutics.

Global Blood Therapeutics (NASDAQ:GBT) last issued its earnings results on Tuesday, November 6th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.02. During the same quarter in the prior year, the business posted ($0.66) EPS.

GBT has been the subject of a number of analyst reports. Cantor Fitzgerald set a $96.00 price objective on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 23rd. HC Wainwright set a $125.00 price objective on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 23rd. Cowen restated a “buy” rating and issued a $83.00 price objective on shares of Global Blood Therapeutics in a research report on Monday, August 13th. Zacks Investment Research upgraded shares of Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $52.00 price objective for the company in a research report on Friday, August 10th. Finally, ValuEngine lowered shares of Global Blood Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have given a buy rating to the company’s stock. Global Blood Therapeutics has a consensus rating of “Buy” and an average price target of $83.20.

NASDAQ:GBT traded down $4.02 on Monday, reaching $42.66. 4,168,610 shares of the company’s stock were exchanged, compared to its average volume of 1,565,665. The firm has a market capitalization of $2.44 billion, a PE ratio of -15.45 and a beta of 3.65. Global Blood Therapeutics has a 52 week low of $30.15 and a 52 week high of $68.05.

A number of institutional investors have recently made changes to their positions in the business. First Allied Advisory Services Inc. lifted its position in Global Blood Therapeutics by 21.4% during the second quarter. First Allied Advisory Services Inc. now owns 7,950 shares of the company’s stock valued at $359,000 after purchasing an additional 1,400 shares during the last quarter. Tocqueville Asset Management L.P. raised its stake in shares of Global Blood Therapeutics by 16.2% during the third quarter. Tocqueville Asset Management L.P. now owns 10,400 shares of the company’s stock worth $395,000 after acquiring an additional 1,450 shares in the last quarter. Great West Life Assurance Co. Can raised its stake in shares of Global Blood Therapeutics by 42.0% during the second quarter. Great West Life Assurance Co. Can now owns 4,969 shares of the company’s stock worth $224,000 after acquiring an additional 1,469 shares in the last quarter. Sei Investments Co. raised its stake in shares of Global Blood Therapeutics by 12.1% during the second quarter. Sei Investments Co. now owns 13,850 shares of the company’s stock worth $626,000 after acquiring an additional 1,499 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. raised its stake in shares of Global Blood Therapeutics by 29.3% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 6,855 shares of the company’s stock worth $260,000 after acquiring an additional 1,555 shares in the last quarter.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Featured Article: How is Preferred Stock Different from Common Stock?

Get a free copy of the Zacks research report on Global Blood Therapeutics (GBT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply